Insider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Chairman Sells 132,079 Shares of Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating) Chairman Jeffrey M. Leiden sold 132,079 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, July 25th. The shares were sold at an average price of $281.38, for a total transaction of $37,164,389.02. Following the completion of the transaction, the chairman now owns 2,423 shares of the company’s stock, valued at $681,783.74. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $286.99 on Thursday. The company has a current ratio of 4.75, a quick ratio of 4.60 and a debt-to-equity ratio of 0.05. The firm has a 50-day moving average of $275.86 and a 200-day moving average of $258.44. The firm has a market cap of $73.40 billion, a P/E ratio of 30.21, a P/E/G ratio of 2.08 and a beta of 0.50. Vertex Pharmaceuticals Incorporated has a 1-year low of $176.36 and a 1-year high of $296.84.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Rating) last posted its earnings results on Thursday, May 5th. The pharmaceutical company reported $3.16 earnings per share for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.01). The firm had revenue of $2.10 billion for the quarter, compared to analysts’ expectations of $2.07 billion. Vertex Pharmaceuticals had a return on equity of 32.24% and a net margin of 30.84%. The business’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.54 earnings per share. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 12.46 EPS for the current year.

Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its stake in Vertex Pharmaceuticals by 1.7% in the fourth quarter. BlackRock Inc. now owns 23,944,931 shares of the pharmaceutical company’s stock worth $5,258,308,000 after buying an additional 397,036 shares in the last quarter. Vanguard Group Inc. raised its stake in Vertex Pharmaceuticals by 1.6% in the first quarter. Vanguard Group Inc. now owns 20,473,471 shares of the pharmaceutical company’s stock worth $5,342,963,000 after buying an additional 317,629 shares in the last quarter. Capital World Investors raised its stake in Vertex Pharmaceuticals by 9.9% in the first quarter. Capital World Investors now owns 12,666,130 shares of the pharmaceutical company’s stock worth $3,305,417,000 after buying an additional 1,145,275 shares in the last quarter. State Street Corp raised its stake in Vertex Pharmaceuticals by 0.3% in the fourth quarter. State Street Corp now owns 12,356,915 shares of the pharmaceutical company’s stock worth $2,713,579,000 after buying an additional 33,499 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in Vertex Pharmaceuticals by 15.2% in the fourth quarter. Alliancebernstein L.P. now owns 10,443,771 shares of the pharmaceutical company’s stock worth $2,293,452,000 after buying an additional 1,374,923 shares in the last quarter. 89.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on VRTX shares. Morgan Stanley upgraded shares of Vertex Pharmaceuticals from an “underweight” rating to an “equal weight” rating and set a $250.00 price objective for the company in a research note on Tuesday, May 3rd. Cowen upped their price target on shares of Vertex Pharmaceuticals from $305.00 to $310.00 and gave the stock an “outperform” rating in a report on Monday, June 13th. Wells Fargo & Company upped their target price on shares of Vertex Pharmaceuticals from $300.00 to $305.00 in a research report on Friday, May 6th. Argus upped their target price on shares of Vertex Pharmaceuticals from $275.00 to $280.00 and gave the stock a “buy” rating in a research report on Monday, June 13th. Finally, StockNews.com assumed coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, March 31st. They issued a “strong-buy” rating for the company. Six investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $287.68.

About Vertex Pharmaceuticals

(Get Rating)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Further Reading

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.